Abstracts tagged "Patient reported outcomes"

Abstract Number: 2328 • ACR Convergence 2023
Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial
Marta Mosca¹, Laurent Arnaud², Anca Askanase³, Coburn Hobar⁴, Brandon Becker⁵, Shalabh Singhal⁴, Subhashis Banerjee⁴, Samantha Pomponi⁴, Jiyoon Choi⁵, Adrian Coles⁵ and Vibeke Strand⁶, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²University Hospitals of Strasbourg, Strasbourg, France, ³Columbia University Medical Center, New York, NY, ⁴Bristol Myers Squibb, Princeton, NJ, ⁵Bristol Myers Squibb, Lawrenceville, NJ, ⁶Stanford University, Portola Valley, CA
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in the US, EU, and other countries for treatment of adults…
Abstract Number: 0365 • ACR Convergence 2023
Establishing a Multidisciplinary Registry for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: Insights into Patient Outcomes and Management Challenges
Stacey Tarvin¹, Amy Rakestraw², Jessica Lee², N. Shaun Matthews³, Susan H. Ballinger² and Christina M. Sparks², ¹Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ²Indiana University School of Medicine, Indianapolis, IN, ³Indiana University School of Dentistry, Indianapolis, IN
Background/Purpose: Temporomandibular joint (TMJ) arthritis, a condition frequently overlooked in patients with JIA, can result in joint damage if not promptly treated. Such damage presents…
Abstract Number: 0510 • ACR Convergence 2023
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
Philip J. Mease¹, Maxime Dougados², Maureen Dubreuil³, Marina Nighat Magrey⁴, Helena Marzo-Ortega⁵, Martin Rudwaleit⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Ute Massow⁹, Vanessa Taieb¹⁰ and Atul Deodhar¹¹, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²Department of Rheumatology, Hôpital Cochin, University of Paris Cité, Paris, France, ³Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁴Case Western Reserve University, University Hospitals, Cleveland, OH, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Oosterzele, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Colombes, France, ¹¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 studies BE MOBILE 1 and…
Abstract Number: 1039 • ACR Convergence 2023
Cross-Sectional Associations of Ultrasound Features with Symptom Outcomes at the Knee: A Community-based Study
Katherine Yates¹, Carolina Alvarez², Todd Schwartz³, Serena Savage-Guin⁴, Jordan Renner⁴, Catherine Bakewell⁵, Minna Kohler⁶, Janice Lin⁷, Jonathan Samuels⁸ and Amanda Nelson⁴, ¹University of North Carolina Medical Center, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Intermountain Healthcare, Salt Lake City, UT, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Stanford University, Palo Alto, CA, ⁸NYU Langone, Rye Brook, NY
Background/Purpose: Ultrasound (US) allows for visualization of many features of knee osteoarthritis (KOA) including osteophytes, meniscal extrusion, synovitis, and articular cartilage damage. Additionally, US is…
Abstract Number: 1279 • ACR Convergence 2023
What Is the Nature of Functional Problems in People with Rheumatoid Arthritis and Severe Disability; An Analysis Using the International Classification of Functioning, Disability and Health as a Reference
Max Teuwen¹, Salima van Weely¹, Thea Vliet Vlieland², Thom Douw³, Manja van Wissen¹, Alfons den Broeder⁴, Dirkjan van Schaardenburg⁵, Cornelia van den Ende⁴ and Maaike gademan¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leids University Medical Center, Leiden, Netherlands, ³Leiden University of Applied Sciences, Leiden, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: There is a lack of knowledge about the limitations in activities and participation experienced by a subgroup of people with rheumatoid arthritis (RA) and…
Abstract Number: 1427 • ACR Convergence 2023
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-bearing Joint Regions: A Post Hoc Subgroup Analysis of the Phase 3, Randomized, SELECT-PsA 1 and SELECT-PsA 2 Trials
Kristi Mizelle¹, William R Tillett², Mira Ali³, Thomas Iyile³, Tianming Gao³, Arathi Setty³, Jessica A Walsh⁴ and Laura Coates⁵, ¹Tidewater Physicians Multispecialty Group, Newport News, VA, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³AbbVie, Inc., North Chicago, IL, ⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: Involvement of weight-bearing joints in patients with PsA can be associated with reduced activities of daily living and quality of life. Upadacitinib (UPA) is…
Abstract Number: 1965 • ACR Convergence 2023
Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Idiopathic Inflammatory Myopathies: Results from the COVAD Study
Mrinalini Dey¹, Rudra Prosad Goswami², Parikshit Sen³, Samuel Shinjo⁴, Nelly Ziade⁵, Ioannis Parodis⁶, Mrudula Joshi⁷, Marcin Milchert⁸, Abraham Edgar Gracia-Ramos⁹, Lorenzo Cavagna¹⁰, Vishwesh Agarwal¹¹, Johannes Knitza¹², Jessica Day¹³, Hector Chinoy¹⁴, COVAD Study Group¹⁵, Vikas Agarwal¹⁶, Rohit Aggarwal¹⁷ and Latika Gupta¹⁸, ¹Queen Elizabeth Hospital, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom, ²Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India, ³Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ⁴Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil, ⁵Saint-Joseph University, Beirut, Lebanon, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ⁸Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ⁹Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, ¹⁰Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ¹¹Mahatma Gandhi Missions Medical College, Lucknow, India, ¹²Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ¹³Walter and Eliza Hall Institute, Melbourne, Australia, ¹⁴The University of Manchester, Sale, United Kingdom, ¹⁵-, -, ¹⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁷University of Pittsburgh, Pittsburgh, PA, ¹⁸Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: Disease activity assessment is key in the management of patients with idiopathic inflammatory myopathies (IIM). However, patients' perception of disease may differ from clinicians.…
Abstract Number: 2196 • ACR Convergence 2023
Females with Axial Spondyloarthritis Report Higher Burden of Disease and Worse Patient-reported Outcomes. Results from the International Map of Axial Spondyloarthritis (IMAS)
Victoria Navarro-Compán¹, Marco Garrido-Cumbrera², Denis Poddubnyy³, Christine Bundy⁴, Souzi Makri⁵, Jose Correa Fernandez⁶, Shashank Murlidhar Akerkar⁷, Lillann Wermskog⁸, Elie Karam⁹, Asif Siddiqui¹⁰ and Fernando Sommerfleck¹¹, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²University of Seville, Sevilla, Spain, ³Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Cardiff University, Cardiff, United Kingdom, ⁵Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, ⁶Universidad de Sevilla, Health & Territory Research (HTR), Sevilla, Spain, ⁷Mumbai Arthritis Clinic, Mumbai, India, ⁸Spondyloarthritis Association of Norwary (SPAFO);Axial Spondyloarthritis International Federation (ASIF), Oslo, Norway, ⁹Canadian Spondylitis Association (CSA), Toronto, ON, Canada, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Sanatorio Julio Mendez, Buenos Aires, Argentina
Background/Purpose: There is increasing evidence of differences between males and females in axial spondyloarthritis (axSpA), but the source is restricted to specific geographic locations or…
Abstract Number: 2500 • ACR Convergence 2023
Suicidal Ideation and Self-Efficacy in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao¹, Jessica Williams², Hilton Mozee¹, Cristina Drenkard¹ and S. Sam Lim¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: Suicidal ideation is more common in SLE than in other chronic diseases. Targeted interventions are needed to reduce morbidity and mortality. Bandura’s theory of…
Abstract Number: 0368 • ACR Convergence 2023
Surveying Psychological Resilience and Pain in a Cross-Section of JIA Patients
Daniella Schocken and Tracy Ting, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Pain trajectories vary in JIA, with some patients developing chronic pain over the course of their illness. Adaptation and recovery under stressful or traumatic…
Abstract Number: 0521 • ACR Convergence 2023
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies
Martin Rudwaleit¹, Victoria Navarro-Compán², Atul Deodhar³, Maureen Dubreuil⁴, Michael Frank Mørup⁵, Vanessa Taieb⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Ute Massow⁹, Thomas Vaux¹⁰ and Annelies Boonen¹¹, ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁴Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁵UCB Pharma, Copenhagen, Denmark, ⁶UCB Pharma, Colombes, France, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Oosterzele, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: The clinical manifestations of axial spondyloarthritis (axSpA) limit physical function and work productivity, posing an economic burden to patients (pts) and society.1 Bimekizumab (BKZ),…
Abstract Number: 1108 • ACR Convergence 2023
Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout
Brian LaMoreaux¹, Chelsea McKibbon², Katie Obermeyer¹, Lissa Padnick-Silver¹, Gerald Smith², Jiaxuan Wang² and Haridarshan Patel¹, ¹Horizon Therapeutics, Deerfield, IL, ²Cytel Inc., Vancouver, BC, Canada
Background/Purpose: Gout is an inflammatory arthritis that results in severe joint inflammation, pain, disability, and lower quality of life (QoL). Determining minimal clinically important differences…
Abstract Number: 1294 • ACR Convergence 2023
Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Using Rasch Measurement Theory and Cognitive Interviewing to Achieve More Meaningful Measurement
Tim Pickles¹, Mike Horton², Karl Bang Christensen³, Rhiannon Phillips⁴, David Gillespie¹, Neil Mo⁵ and Ernest Choy⁶, ¹Cardiff University, Cardiff, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Copenhagen, Copenhagen, Denmark, ⁴Cardiff Metropolitan University, Cardiff, United Kingdom, ⁵Swansea Bay University Health Board, Port Talbot, United Kingdom, ⁶Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Disease Activity (DA) monitoring is a standard of care in Rheumatoid Arthritis (RA). A systematic review of Patient Reported Outcome Measures (PROMs) for RA…
Abstract Number: 1428 • ACR Convergence 2023
Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
Laure Gossec¹, Xenofon Baraliakos², James Galloway³, Lars Erik⁴, Vilija Oke⁵, Petros Sfikakis⁶, Emmanouil Rampakakis⁷, Mohamed Sharaf⁸, Frederic Lavie⁹ and Iain McInnes¹⁰, ¹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³King's College London, London, United Kingdom, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Kapodistrian University of Athens Medical School, Athens, Greece, ⁷JSS Medical Research, Saint-Laurent, QC, Canada, ⁸Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In the Phase 3b COSMOS trial, guselkumab (GUS), a fully human IL-23p19 inhibitor (i), was associated with significantly greater improvements vs placebo (PBO) in…
Abstract Number: 2024 • ACR Convergence 2023
Patient-Reported Outcomes in Patients with Lupus Nephritis: A Post Hoc Analysis of Control Arm Data from Two Completed Phase III Randomized Clinical Trials
Christophe T. Tchakoute¹, Huiyan (Ashley) Mao², Gene Wallenstein¹, Jorge Ross Terres¹, Seitaro Yoshida¹ and Lisa Lindsay¹, ¹Genentech, Inc., South San Francisco, CA, ²Hoffmann-La Roche Ltd, Mississauga, ON, Canada
Background/Purpose: Lupus nephritis (LN) is a severe and common (50%) organ-threatening manifestation of systemic lupus erythematosus and is associated with a high risk of progression…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].